Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | GYS1 | P13807 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.49 |
| ▸ | GRK5 | P34947 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1611778 | 1.00 | P2RX7 (0.60) | P2RX7KMT2ASIGMAR1GYS1POLB | |
| SCHEMBL1612508 | 0.85 | P2RX7 (0.57) | P2RX7KMT2ASIGMAR1POLBALDH1A1 | |
| SCHEMBL290014 | 0.85 | P2RX7 (0.57) | P2RX7KMT2ASIGMAR1POLBALDH1A1 | |
| SCHEMBL288978 | 0.84 | P2RX7 (0.55) | P2RX7KMT2ASIGMAR1GYS1ALDH1A1 | |
| SCHEMBL1611845 | 0.84 | P2RX7 (0.55) | P2RX7KMT2ASIGMAR1GYS1ALDH1A1 | |
| SCHEMBL287987 | 0.83 | HCRTR1 (0.58) | P2RX7GYS1 | |
| SCHEMBL1612232 | 0.83 | HCRTR1 (0.58) | P2RX7GYS1 | |
| SCHEMBL289327 | 0.81 | CAPN1 (0.69) | P2RX7 | |
| SCHEMBL1611971 | 0.81 | CAPN1 (0.69) | P2RX7 | |
| SCHEMBL288870 | 0.81 | CAPN1 (0.69) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427429-B1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2017-02-15 | — | — | EP | disclosed |
| US-9527811-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-12-27 | — | — | US | disclosed |
| US-9018206-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-28 | — | — | US | disclosed |
| US-20150099786-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-04-09 | — | — | US | disclosed |
| US-20130150367-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT LABORATORIES (US) | 2013-06-13 | — | — | US | disclosed |
| US-8283363-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBOTT LABORATORIES (US) | 2012-10-09 | — | — | US | disclosed |
| US-8236798-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBOTT GMBH & CO. KG (DE) | 2012-08-07 | — | — | US | disclosed |
| EP-2427429-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | Abbott GmbH & Co. KG (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20110086879-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2011-04-14 | — | — | US | disclosed |
| WO-2010128102-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286146-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | P2RX7 1852/4885KMT2A 1409/4885SIGMAR1 1745/4885 |
| US-20130150367-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | P2RX7 1852/4885KMT2A 1409/4885SIGMAR1 1745/4885 |
| US-20110086879-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | P2RX7 1852/4885KMT2A 1409/4885SIGMAR1 1745/4885 |
| US-20150099786-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAPN1, CAPN2, CAPNS1 | P2RX7 1852/4885KMT2A 1409/4885SIGMAR1 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.